These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 16114114)

  • 1. Human Genome Sciences will start clinical trials with anti-CCR5 monoclonal antibody.
    IAVI Rep; 2004 Dec-2005 Mar; 9(1):15. PubMed ID: 16114114
    [No Abstract]   [Full Text] [Related]  

  • 2. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Several commercially available anti-CCR5 monoclonal antibodies lack specificity and should be used with caution.
    Bernstone L; van Wilgenburg B; James W
    Hybridoma (Larchmt); 2012 Feb; 31(1):7-19. PubMed ID: 22316480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.
    Lalezari J; Yadavalli GK; Para M; Richmond G; Dejesus E; Brown SJ; Cai W; Chen C; Zhong J; Novello LA; Lederman MM; Subramanian GM
    J Infect Dis; 2008 Mar; 197(5):721-7. PubMed ID: 18266604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7.
    Aarons EJ; Beddows S; Willingham T; Wu L; Koup RA
    Virology; 2001 Sep; 287(2):382-90. PubMed ID: 11531415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
    Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
    Khurana S; Kennedy M; King LR; Golding H
    J Virol; 2005 Jun; 79(11):6791-800. PubMed ID: 15890918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.
    Ji C; Brandt M; Dioszegi M; Jekle A; Schwoerer S; Challand S; Zhang J; Chen Y; Zautke L; Achhammer G; Baehner M; Kroetz S; Heilek-Snyder G; Schumacher R; Cammack N; Sankuratri S
    Antiviral Res; 2007 May; 74(2):125-37. PubMed ID: 17166600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140).
    Shearer WT; DeVille JG; Samson PM; Moye JH; Fletcher CV; Church JA; Spiegel HM; Palumbo P; Fenton T; Smith ME; Graham B; Kraimer JM; Olson WC
    J Allergy Clin Immunol; 2006 Aug; 118(2):518-21. PubMed ID: 16890780
    [No Abstract]   [Full Text] [Related]  

  • 10. Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4.
    Misumi S; Takamune N; Ido Y; Hayashi S; Endo M; Mukai R; Tachibana K; Umeda M; Shoji S
    Biochem Biophys Res Commun; 2001 Aug; 285(5):1309-16. PubMed ID: 11478800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
    Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
    AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies.
    Zhang J; Rao E; Dioszegi M; Kondru R; DeRosier A; Chan E; Schwoerer S; Cammack N; Brandt M; Sankuratri S; Ji C
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1386-97. PubMed ID: 17242138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of acute and chronic cardiac allograft rejection in mice by inhibition of chemokine receptor 5 in combination with cyclosporine A.
    Li J; Xia J; Zhang K; Xu L
    J Surg Res; 2009 Nov; 157(1):81-90. PubMed ID: 19577762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies.
    Blanpain C; Vanderwinden JM; Cihak J; Wittamer V; Le Poul E; Issafras H; Stangassinger M; Vassart G; Marullo S; Schlndorff D; Parmentier M; Mack M
    Mol Biol Cell; 2002 Feb; 13(2):723-37. PubMed ID: 11854425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120.
    Binley JM; Ngo-Abdalla S; Moore P; Bobardt M; Chatterji U; Gallay P; Burton DR; Wilson IA; Elder JH; de Parseval A
    Retrovirology; 2006 Jul; 3():39. PubMed ID: 16817962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody/receptor protein immunocomplex in human and mouse cortical nerve endings amplifies complement-induced glutamate release.
    Merega E; Prisco SD; Severi P; Kalfas F; Pittaluga A
    Neurosci Lett; 2015 Jul; 600():50-5. PubMed ID: 26049008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The chemoattraction of lymphocytes by rheumatoid arthritis - synovial fluid is not dependent on the chemokine receptor CCR5.
    Santiago B; Galindo M; Rivero M; Brehmer MT; Mateo I; Pablos JL
    Rheumatol Int; 2002 Jul; 22(3):107-11. PubMed ID: 12111085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cyclic dodecapeptide-multiple-antigen peptide conjugate from the undecapeptidyl arch (from Arg(168) to Cys(178)) of extracellular loop 2 in CCR5 as a novel human immunodeficiency virus type 1 vaccine.
    Misumi S; Nakajima R; Takamune N; Shoji S
    J Virol; 2001 Dec; 75(23):11614-20. PubMed ID: 11689643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins.
    Hill CM; Kwon D; Jones M; Davis CB; Marmon S; Daugherty BL; DeMartino JA; Springer MS; Unutmaz D; Littman DR
    Virology; 1998 Sep; 248(2):357-71. PubMed ID: 9721244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.